|Title:||Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response||Authors:||YU-LI CHEN
|Issue Date:||2012||Publisher:||John Wiley and Sons Ltd||Journal Volume:||6||Journal Issue:||3||Start page/Pages:||360-369||Source:||Molecular Oncology||Abstract:||
The alpha-folate receptor (α-FR) is highly-expressed in various non-mucinous tumors of epithelial origin, including ovarian carcinoma. The aim of this study was to investigate the relationship between alpha-folate receptor (α-FR) and the clinico-pathologic features and outcomes of serous ovarian carcinoma patients and the possible mechanism of α-FR to chemo-resistance. Therefore, semi-quantitative reverse-transcription polymerase chain reactions for α-FR expression were performed in the 91 specimens of serous ovarian carcinomas. The expression of α-FR in each ovarian cancer tissue specimen was defined as the ratio of density of α-FR to density of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). . In vitro apoptotic experiments were tested in the original OVCAR-3 tumor cells and various OVCAR-3 α-FR-transfectants. Patients with an increased α-FR expression level had poorer responses to chemotherapy (per α-FR expression level increase: odds ratio (OR): 8.97 (95% confidence interval (CI): 1.40-57.36), . p = 0.021). An increased α-FR expression level was an independently poor prognostic factor for disease free interval (DFI) (per α-FR expression level increase: hazard ratio (HR): 2.45 (95% CI: 1.16-5.18), . p = 0.02) and had a negative impact on overall survival (OS) of these serous ovarian cancer patients (per α-FR expression level increase: HR: 3.6 (95% CI: 0.93-13.29), . p = 0.03) by multivariate analyses. α-FR inhibited cytotoxic drug-induced apoptosis in our . in vitro apoptotic assays. α-FR could induce chemo-resistance via regulating the expression of apoptosis-related molecules, Bcl-2 and Bax. Therefore, α-FR can be a potential biomarker for the prediction of chemotherapeutic responses and clinical prognosis. It also could be the target of ovarian cancer treatment. ? 2011 Federation of European Biochemical Societies.
|DOI:||10.1016/j.molonc.2011.11.010||SDG/Keyword:||alpha folate receptor; caspase 3; caspase 7; cisplatin; cyclophosphamide; folate receptor; glyceraldehyde 3 phosphate dehydrogenase; lipocortin 5; paclitaxel; topotecan; unclassified drug; apoptosis; article; cancer chemotherapy; cancer growth; cancer patient; cancer prognosis; cancer survival; clinical feature; controlled study; disease free interval; female; human; human cell; human tissue; immunoblotting; immunoprecipitation; in vitro study; major clinical study; multiple cycle treatment; outcome assessment; ovary carcinoma; overall survival; priority journal; protein expression; reverse transcription polymerase chain reaction; serous ovarian carcinoma; treatment response; tumor cell
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.